Innoviva Q2 2026 revenue up 19% to $119.6M; net loss $83.4M on $161M fair-value charge

Innoviva, Inc.

Total revenue $119.6M (+19% YoY); net product sales $51.8M (+46% YoY) driven by IST growth.
Net loss $83.4M ($1.14 loss per share) due to $161M unfavorable fair-value change in equity investments (Armata).
Royalty revenue from GSK stable at $59.8M; IST U.S. net product sales $36.6M (+26% YoY).
Launched Nortiva Bio for long-acting oral drug delivery; XACDURO licensing deal with Dr. Reddy's for emerging markets.
Repurchased 1.4M shares for $31.4M in Q2; cash $570.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.